The long-term growth story for AstraZeneca PLC beyond 2030 is increasingly focused on next-generation cell therapies and ...

Astrazeneca boss Pascal Soriot was handed his largest ever pay package last year - taking his total earnings at the pharma ...

AstraZeneca PLC closed 0.08% below its 52-week high of £155.54, which the company achieved on February 24th.

Increase of 6.4% comes as drugmaker reports strong profit growth, despite cancelling UK investment projects ...

AstraZeneca received FDA approval for Calquence with venetoclax, creating the first all oral, fixed duration regimen for ...

Why AstraZeneca is on investors’ radar today AstraZeneca (LSE:AZN) has drawn attention after a period of solid recent share ...

A federal appellate court has handed down the first appellate-level decision addressing the merits of drug manufacturers’ challenges to the Inflation Reduction Act of 2022's (IRA) Medicare Drug ...

AstraZeneca has secured approval in the US for Calquence (acalabrutinib) plus venetoclax as the first all-oral, fixed-duration regimen to treat adults with chronic lymphocytic leu ...

After another swing and a miss for AstraZeneca's Fasenra in chronic obstructive pulmonary disease (COPD), the company is pivoting to other options in its portfolio that might have potential to treat ...

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space. The ...

AstraZeneca has secured a key regulatory win in its effort to reclaim the lead in the BTK inhibitor market, with the FDA approving its combination of Calquence plus Venclexta as the first all-oral, ...

AstraZeneca Pharmaceuticals LP, for now, must abide by a Hawaii law that requires it to deliver discounted drugs to ...